Midatech Pharma appoints Strand Hanson as Nominated and Financial Adviser

Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicine, has announced the appointment of Strand Hanson Limited as the Company’s Nominated and Financial Adviser with immediate effect.

Turner Pope Investments Ltd will be the Company’s sole broker.

Midatech Pharma is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Midatech pharma

    More articles like this

    Midatech pharma

    Midatech Pharma pleased with the progress made in H1 2022

    Midatech Pharma Plc (LON:MTPH; NASDAQ: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced its unaudited interim results for the six months ended 30 June 2022 which will also be made

    Midatech pharma

    Midatech Pharma MTX110 study to be presented at ISPNO 2022

    Midatech Pharma PLC (LON:MTPH) an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, has announced that investigators from Columbia University Irving Medical Center and New York-Presbyterian will present interim results from their ongoing Phase 1

    Midatech pharma

    Midatech Pharma granted FDA Fast Track designation for MTX110

    Midatech Pharma PLC (LON:MTPH), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, has announced that upon submitting an application to the U.S. Food and Drug Administration, its development programme of MTX110 for the treatment of

    Midatech pharma

    Midatech Pharma total gross revenue increases to £0.58m

    Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced its audited preliminary results for the year ended 31 December 2021. 2021 HIGHLIGHTS Operational · In June 2021, in an

    Midatech pharma

    Midatech Pharma extends R&D collaboration with Janssen

    Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced an extension of its existing R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July 2020. On 17

    Midatech pharma

    Midatech Pharma extends R&D collaboration with Janssen

    Midatech Pharma PLC (LON:MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced the extension of its R&D collaboration with Janssen Pharmaceutica NV originally announced on 21 July 2020. On

    Midatech pharma

    Midatech Pharma formally opens its new Cardiff headquarters

    Midatech Pharma PLC (LON:MTPH), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, has announced the formal opening today of its new headquarters, incorporating purpose built laboratory facilities and offices at 1 Caspian

    Midatech pharma

    Midatech Pharma investor webinar 10th September 2020

    Midatech Pharma plc (LON:MTPH ; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, will be hosting an investor webinar at 2.00pm London time on the 10th September 2020, the day of